Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
results entities : Takeda pharmaceutical company limited save search
Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia
Published: 2024-03-13 (Crawled : 13:30) - biospace.com/
TAK | News | $13.19 0.23% 740K
|
Health Technology
|
| O: 0.21%
H: 0.17%
C: 0.14%
tak-079 positive topline potential results study
Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D Priorities
Published: 2024-02-13 (Crawled : 19:00) - biospace.com/
TAK | News | $13.19 0.23% 740K
|
Health Technology
|
| O: 0.14%
H: 0.35%
C: 0.07%
XNCR | $18.325 -3.3% 220K
|
Health Technology
|
| O: -3.56%
H: 2.91%
C: -3.34%
MOR | $17.96 -0.5% 72K
|
Health Technology
|
| O: -0.4%
H: 0.23%
C: -0.46%
MGNX | $15.42 -4.05% 240K
|
Health Technology
|
| O: -5.25%
H: 2.94%
C: 2.18%
INCY | $52.07 -1.42% 800K
|
Health Technology
|
| O: 3.8%
H: 1.1%
C: -1.17%
financial
Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2023 Financial Results and Provides Financial Expectations for 2024
Published: 2024-02-07 (Crawled : 12:00) - prnewswire.com
TAK | News | $13.19 0.23% 740K
|
Health Technology
|
| O: 0.07%
H: 0.42%
C: 0.07%
NBIX M | $130.31 -1.68% 260K
|
Health Technology
|
| O: -5.57%
H: 6.04%
C: 0.96%
financial results
Takeda Announces Third-Quarter FY2023 Results; On-Track Towards Full-Year Management Guidance With Strong Momentum in Growth & Launch Products
Published: 2024-02-01 (Crawled : 09:00) - biospace.com/
TAK | News | $13.19 0.23% 740K
|
Health Technology
|
| O: 0.48%
H: 0.0%
C: -1.98%
fy2023 management momentum growth
Exelixis Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024
Published: 2024-01-25 (Crawled : 22:00) - biospace.com/
TAK | News | $13.19 0.23% 740K
|
Health Technology
|
| O: -0.27%
H: 0.07%
C: -0.07%
EXEL | $22.28 -0.93% 960K
|
Health Technology
|
| O: 0.14%
H: 1.4%
C: -0.23%
ntact-02 asco cancer trial results
ImmunoGen Reports Recent Progress and Third Quarter 2023 Financial Results
Published: 2023-11-02 (Crawled : 13:00) - biospace.com/
TAK | News | $13.19 0.23% 740K
|
Health Technology
|
| O: 1.03%
H: 0.73%
C: 0.58%
LLY | $727.48 -2.48% 2M
|
Health Technology
|
| O: 4.42%
H: 0.0%
C: 0.0%
IMGN | $31.23 0.03% 49M
|
Health Technology
|
| O: 5.09%
H: 5.48%
C: -1.27%
financial results
Incyte Reports 2023 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
Published: 2023-10-31 (Crawled : 00:00) - biospace.com/
TAK | News | $13.19 0.23% 740K
|
Health Technology
|
| O: 1.05%
H: 0.74%
C: 0.74%
XNCR | $18.325 -3.3% 220K
|
Health Technology
|
| O: -0.41%
H: 2.1%
C: 1.11%
MOR | $17.96 -0.5% 72K
|
Health Technology
|
| O: 4.23%
H: 0.12%
C: -1.97%
MGNX | $15.42 -4.05% 240K
|
Health Technology
|
| O: 0.0%
H: 2.13%
C: 1.16%
INCY | $52.07 -1.42% 800K
|
Health Technology
|
| O: -0.39%
H: 4.09%
C: 3.8%
financial results
Takeda Announces FY2023 H1 Results; Updates Full-Year Forecasts While Remaining on Track Towards Management Guidance
Published: 2023-10-26 (Crawled : 08:00) - biospace.com/
TAK | News | $13.19 0.23% 740K
|
Health Technology
|
| O: -4.69%
H: 0.69%
C: -3.18%
fy2023 management
Takeda Announces Positive Topline Results from Phase 2b Study Evaluating TAK-279, a Highly Selective Oral TYK2 Inhibitor, for the Treatment of Active Psoriatic Arthritis
Published: 2023-09-11 (Crawled : 12:00) - biospace.com/
TAK | News | $13.19 0.23% 740K
|
Health Technology
|
| O: 1.31%
H: 0.91%
C: 0.52%
tak-279 active positive treatment topline results study
Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer
Published: 2023-08-21 (Crawled : 05:00) - globenewswire.com
TAK | News | $13.19 0.23% 740K
|
Health Technology
|
| O: -0.4%
H: 0.6%
C: 0.47%
EXEL | $22.28 -0.93% 960K
|
Health Technology
|
| O: 0.28%
H: 1.32%
C: 0.99%
ntact-02 positive cancer trial results
Arrowhead Pharmaceuticals Reports Fiscal 2023 Third Quarter Results
Published: 2023-08-07 (Crawled : 21:00) - biospace.com/
TAK | News | $13.19 0.23% 740K
|
Health Technology
|
| O: 0.62%
H: 0.62%
C: 0.42%
GSK | $39.585 0.8% 1.1M
|
Health Technology
|
| O: 0.35%
H: 0.41%
C: 0.41%
ARWR | $22.1 -2.26% 390K
|
Health Technology
|
| O: 0.0%
H: 0.44%
C: -2.65%
pharmaceuticals results
Incyte Reports 2023 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
Published: 2023-08-01 (Crawled : 15:00) - biospace.com/
TAK | News | $13.19 0.23% 740K
|
Health Technology
|
| O: -2.23%
H: 2.28%
C: 1.34%
XNCR | $18.325 -3.3% 220K
|
Health Technology
|
| O: -0.74%
H: 0.0%
C: 0.0%
REPL | $6.56 -5.88% 310K
|
Health Technology
|
| O: 2.63%
H: 1.14%
C: -2.65%
MOR | $17.96 -0.5% 72K
|
Health Technology
|
| O: -0.14%
H: 4.77%
C: 4.77%
MGNX | $15.42 -4.05% 240K
|
Health Technology
|
| O: 0.0%
H: 4.19%
C: 2.31%
INCY | $52.07 -1.42% 800K
|
Health Technology
|
| O: 2.75%
H: 0.44%
C: -2.72%
financial results
Neurocrine Biosciences Reports Second Quarter 2023 Financial Results and Raises 2023 INGREZZA Sales Guidance
Published: 2023-08-01 (Crawled : 15:00) - biospace.com/
TAK | News | $13.19 0.23% 740K
|
Health Technology
|
| O: -2.23%
H: 2.28%
C: 1.34%
NBIX M | $130.31 -1.68% 260K
|
Health Technology
|
| O: 0.6%
H: 1.95%
C: 0.92%
sales ingrezza financial results
Takeda Reports Strong First Quarter FY2023 Results, Driven by Growth & Launch Products
Published: 2023-07-27 (Crawled : 10:00) - biospace.com/
TAK | News | $13.19 0.23% 740K
|
Health Technology
|
| O: 0.97%
H: 1.35%
C: 0.06%
fy2023 growth
Takeda and HUTCHMED Announce Publication of Phase 3 FRESCO-2 Results in The Lancet
Published: 2023-06-16 (Crawled : 10:00) - biospace.com/
TAK | News | $13.19 0.23% 740K
|
Health Technology
|
| O: -0.06%
H: 0.53%
C: -0.31%
LLY | $727.48 -2.48% 2M
|
Health Technology
|
| O: 0.41%
H: 0.26%
C: -1.77%
lancet publication results
HUTCHMED and Takeda Announce Publication of Phase III FRESCO-2 Results in The Lancet
Published: 2023-06-16 (Crawled : 01:00) - globenewswire.com
TAK | News | $13.19 0.23% 740K
|
Health Technology
|
| O: -0.06%
H: 0.53%
C: -0.31%
HCM | $16.44 0.49% 28K
|
Health Technology
|
| O: 3.79%
H: 4.16%
C: 1.53%
publication results
Neurocrine Biosciences Reports First Quarter 2023 Financial Results
Published: 2023-05-03 (Crawled : 12:00) - biospace.com/
TAK | News | $13.19 0.23% 740K
|
Health Technology
|
| O: 0.36%
H: 0.57%
C: 0.18%
VYGR | $7.38 -2.25% 250K
|
Health Technology
|
| O: 5.76%
H: 6.4%
C: 5.04%
NBIX M | $130.31 -1.68% 260K
|
Health Technology
|
| O: 3.43%
H: 0.92%
C: -7.83%
financial results
Incyte Reports 2023 First Quarter Financial Results and Provides Updates on Key Clinical Programs
Published: 2023-05-02 (Crawled : 12:00) - biospace.com/
TAK | News | $13.19 0.23% 740K
|
Health Technology
|
| O: -0.42%
H: 0.48%
C: 0.3%
XNCR | $18.325 -3.3% 220K
|
Health Technology
|
| O: -0.63%
H: 0.15%
C: -1.78%
MOR | $17.96 -0.5% 72K
|
Health Technology
|
| O: 0.75%
H: 0.0%
C: -3.15%
MGNX | $15.42 -4.05% 240K
|
Health Technology
|
| O: -1.62%
H: 2.47%
C: -6.58%
INCY | $52.07 -1.42% 800K
|
Health Technology
|
| O: -9.64%
H: 5.99%
C: 2.76%
financial results
Takeda Announces Results From Phase 4 Vedolizumab Study in Patients With Chronic Pouchitis Published in New England Journal of Medicine
Published: 2023-03-30 (Crawled : 14:00) - biospace.com/
TAK | News | $13.19 0.23% 740K
|
Health Technology
|
| O: -0.67%
H: 0.89%
C: -0.06%
results study
Phase 2b Clinical Trial Results for TYK2 Inhibitor Presented at American Academy of Dermatology Annual Meeting
Published: 2023-03-20 (Crawled : 14:20) - biospace.com/
TAK | News | $13.19 0.23% 740K
|
Health Technology
|
| O: -0.73%
H: 0.78%
C: 0.61%
meeting trial
Gainers vs Losers
| 71% | 29% |
Top 10 Gainers
AGBA | News | $1.27 217.5% 120M
|
Finance
EGOX | $0.0503 39.72% 320M
|
RWOD | $10.52 31.56% 5.9M
|
n/a
ZCMD | $1.905 31.38% 30M
|
Commercial Services
NVFY | $2.71 28.44% 31M
|
Consumer Durables
MRDB 4 | $0.536 27.65% 2M
|
n/a
BSFC | $0.0822 27.64% 75M
|
Manufacturing
TPET | $0.4121 25.68% 45M
|
n/a
INDO | $5.1 25.0% 15M
|
Energy Minerals
CHRO | $1.53 24.9% 100K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.